Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug according to the results from a phase 3 clinical trial.
from Latest Science News -- ScienceDaily https://ift.tt/2Zjxsqe
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment